Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopy Clear all
Completed Phase 2 Interventional

Study of TDM-180935 in Atopic Dermatitis Patients

NCT06363461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1, TDM-180935 topical vehicle ointment 2
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Rolling Meadows, Illinois • Covington, Louisiana • New Brighton, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 3 Interventional

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT03422822
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
3,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
156
States / cities
Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT06436183
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions
Camoteskimab, Placebo
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis

NCT00828412
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%
Device · Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
3 Months to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

NCT06787586
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions
ATTO-1310, ATTO-1310 Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Encinitas, California • Rocklin, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Not applicable Interventional

Clinic-Based Atopic Dermatitis Therapeutic Patient Education

NCT04352270
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
AD printed educational materials, AD educational videos
Other
Lead sponsor
Boston University
Other
Eligibility
Up to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 25, 2026, 5:16 PM EDT
Active, not recruiting Phase 2 Interventional

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Bryant, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

NCT06810050
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo)
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
12 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Fremont, California • Manhattan Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 25, 2026, 5:16 PM EDT
Not listed Phase 3 Interventional

Metal Panel Allergen Patch Test Study

NCT04500834
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Metal Panel T.R.U.E. Test
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 25, 2026, 5:16 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03736967
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
REGN3500, Dupilumab, REGN3500 + Dupilumab Combo, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 5:16 PM EDT
Withdrawn Not applicable Interventional

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

NCT01695707
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pioglitazone, Placebo (for pioglitazone)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

NCT04306965
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Apremilast
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Not applicable Interventional

A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children

NCT04740892
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Wash IP, Cream IP
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
3 Months to 72 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
High Point, North Carolina • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04773587
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
42
States / cities
Montgomery, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

NCT03667014
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
Dupilumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 25, 2026, 5:16 PM EDT
Withdrawn Not applicable Interventional

A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families

NCT02067234
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Routine Care/Education, Psychoeducation/Coping Prevention
Other · Behavioral
Lead sponsor
Seton Healthcare Family
Other
Eligibility
2 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 25, 2026, 5:16 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Probiotic Supplementation in Breastfed Newborn Infants

NCT02286999
View directory record Official record
Conditions
Atopic Dermatitis, Food Allergies
Interventions
B. infantis, Placebo
Drug
Lead sponsor
Emanual Maverakis, MD
Other
Eligibility
1 Day to 7 Days
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

NCT00130364
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 11 Years
Enrollment
200 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Novartis Pharmaceuticals, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 25, 2026, 5:16 PM EDT
Recruiting Phase 2 Interventional

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

NCT07242638
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata
Interventions
Abrocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

NCT02864498
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Placebo
Drug
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 25, 2026, 5:16 PM EDT
Terminated Not applicable Interventional

Evaluating the Effect of Bathing Additives in Atopic Dermatitis

NCT04001855
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Dilute vinegar (acetic acid), Dilute bleach
Other
Lead sponsor
University of Arizona
Other
Eligibility
5 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Not applicable Interventional

Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis

NCT00985894
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Online Teledermatology Care, Conventional in Office Care
Other
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

NCT04033367
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 25, 2026, 5:16 PM EDT
Completed Phase 4 Interventional

Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects

NCT00139581
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Apr 23, 2008 · Synced Oct 25, 2026, 5:16 PM EDT